Prognostic implications of polymorphisms and interleukin-2 therapy for renal cell carcinoma.
Gardner
Thomas A
TA
Logan
Theodore
T
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D011110:Polymorphism, Genetic; D011379:Prognosis
D000970:Antineoplastic Agents; D007376:Interleukin-2